Approval · Notice of Compliance 27941 · 2022
RANITIDINE: Notice of Compliance 27941
Issued April 8, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27941
- Date
- April 8, 2022
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- PM update to align with CRP. Update to Directions section
- Canadian reference product
- ZANTAC (Sanofi Consumer Health Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RANITIDINE | Not yet assigned | — |
Medicinal ingredients
- RANITIDINE HCL 75 MG per TAB